🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

CytomX Therapeutics, Inc. CTMX R3KPHARMA

Healthcare · Biotechnology · United States
https://www.cytomx.com
Company Profile ↓
$3.65
+105.63% 1Y
Mkt Cap$795.33M
P/E-6.40
P/B2.55
52W High$6.75
52W Low$1.76
Book Value$1.39
EPS (TTM)$-0.57

Company Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 44.9% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $76.20M (-44.8% YoY); net profit $-17.37M.
  • Trailing 12 Months Year-on-year growth — revenue -92.4%, earnings -154.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 44.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:44.92%
1 Year:-92.40%

Compounded Profit Growth

5 Years:-
1 Year:-154.50%

Stock Price Performance

1 Year:+105.63%
6 Months:-27.44%
3 Months:+24.15%
1 Month:+5.49%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 38% of range
$1.76 $6.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)57.53 · Neutral
Price Performance
1M+5.49%
3M+24.15%
6M-27.44%
1Y+105.63%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 44.9% over 5 years.

CONS

  • Trading 45.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-6.40
Industry PE
24.83
Forward P/E
-7.72
PEG Ratio
-
Book Value
$1.39
Price to Book
2.55
P/S
42.14
EV/EBITDA
-5.46
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
44.92%
Profit 5Y
-
Revenue (YoY)
-92.40%
Earnings (YoY)
-154.50%

Profitability & Returns

ROCE
-21.31%
ROE
-37.75%
ROA
-19.58%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-
EPS (TTM)
$-0.57

Balance Sheet & Liquidity

Debt/Equity
1.89
Quick Ratio
9.26
Current Ratio
9.36
Debt
$5.70M
Total Assets
$381.23M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.57%
Chg in Prom Hold
0.05%
FII / Inst Holding
104.07%
Chg in FII Hold
0.24%

Financial Snapshot

Enterprise Value
$795.33M
Total Revenue (TTM)
$18.30M
EBITDA
$-86.21M
Free Cash Flow
$-75.21M
Operating Cash Flow
$-82.41M
Shares Outstanding
217.90M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CTMX CytomX Therapeutics, Inc. R3KPHARMA 3.65 -6.40 $795.33M 0.00% -21.31% -37.75% 44.92% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------11.65M8.75M24.14M27.07M14.18M21.34M12.51M11.47M29.48M9.01M10.71M8.28M49.59M16.61M17.79M15.97M16.29M17.59M9.04M12.85M11.15M23.50M24.72M26.38M41.46M25.11M33.43M50.92M18.66M5.96M10.26M1.42M
Operating Income -4.87M-5.54M-11.27M--16.18M-14.26M-14.92M--8.61M-25.37M-11.03M--15.63M-13.26M-23.18M-25.81M-16.57M-31.23M-25.72M--2.79M-16.14M-14.89M-15.63M-19.20M-22.64M-32.06M-30.05M-29.71M-5.65M-3.35M3.12M11.66M-8.45M4.11M22.62M-1.29M-15.77M-19.67M-23.78M
Net Income -6.21M-5.81M-11.87M-11.49M-16.03M-14.18M-14.66M-14.03M-8.26M-25.22M-10.25M621.00K-15.49M-13.45M-23.43M-32.23M-14.12M-28.96M-23.70M-35.45M12.21M-15.68M-14.71M-15.55M-19.24M-22.58M-31.98M-29.50M-29.06M-3.31M-1.09M2.99M13.79M-6.53M5.74M23.52M-154.00K-14.23M-18.25M-20.67M
R&D Expense 4.66M5.03M9.16M-13.37M12.71M13.34M-14.58M28.08M28.92M-22.46M25.55M27.55M-36.38M30.84M27.97M-42.81M24.07M24.05M22.37M26.10M29.14M30.56M31.16M30.37M21.18M20.67M16.45M22.05M25.17M21.37M18.87M13.32M15.30M19.24M17.60M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 888.00K5.08M7.71M12.85M71.62M59.50M57.49M100.36M37.31M53.16M101.21M138.10M76.20M
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------154.50M107.70M113.11M98.56M
Operating Income -14.96M-29.77M-33.20M-59.59M-46.26M-77.87M-110.89M-48.60M-116.04M-101.33M-6.48M25.00M-22.36M
EBITDA ----------98.89M-4.31M26.76M-20.99M
Interest Expense -------------
Pretax Income ----------99.32M3.32M32.09M-17.13M
Tax Provision ---------03.89M224.00K238.00K
Net Income -15.14M-30.31M-35.37M-58.90M-43.10M-84.60M-102.24M-32.88M-115.87M-99.32M-569.00K31.87M-17.37M
Diluted EPS ----------1.51-0.010.38-0.15
R&D Expense 10.89M28.30M28.36M54.76M92.28M103.87M131.62M112.94M114.19M111.65M77.68M83.38M68.73M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --73.06M197.22M199.13M397.64M457.11M341.28M358.66M339.41M---260.89M201.79M120.53M151.57M
Total Equity -26.05M-44.28M-78.54M126.07M78.48M69.90M130.88M51.11M-7.77M-459.00K-29.74M-54.54M-80.54M-85.75M-47.45M-456.00K99.01M
Cash & Equivalents 14.75M8.70M64.40M59.82M104.64M177.55M247.58M188.43M191.86M205.53M---193.65M17.17M38.05M12.67M
Long Term Debt --1.57M--------------
Total Liabilities --74.89M71.15M120.65M327.75M326.23M290.17M308.86M339.87M326.56M314.62M307.03M346.64M249.24M120.99M52.56M
Current Liabilities --11.16M15.74M35.77M61.15M97.91M85.59M100.92M77.87M87.40M94.64M123.64M152.61M155.91M85.77M46.62M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----2.03M170.37M-75.52M-140.48M5.26M-119.03M-110.79M-56.03M-86.23M-75.59M
Investing Cash Flow ---45.86M-121.27M5.93M79.70M-18.72M22.49M98.26M-150.67M99.70M-59.74M
Financing Cash Flow ---996.00K23.80M139.62M1.63M16.89M110.21M648.00K30.23M7.52M110.45M
Capital Expenditure -732.00K-1.66M-1.59M-2.18M-1.56M-3.79M-3.50M-2.31M-1.61M-1.74M-840.00K-310.00K-220.00K
Free Cash Flow ----4.21M168.81M-79.31M-143.98M2.95M-120.64M-112.53M-56.88M-86.54M-75.81M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -1,684.2%-586.3%-430.5%-463.9%-64.6%-130.9%-192.9%-48.4%-311.0%-190.6%-6.4%18.1%-29.3%
Net Margin % -1,705.3%-597.0%-458.7%-458.5%-60.2%-142.2%-177.8%-32.8%-310.5%-186.8%-0.6%23.1%-22.8%
ROE % 34.2%38.6%-28.1%-75.1%-61.7%-64.6%-200.0%423.0%25,244.0%115.8%1.2%-6,988.8%-17.5%
ROCE % --48.1%-18.3%-36.5%-13.7%-21.7%-43.4%-18.9%-44.4%-93.6%-14.1%71.9%-21.3%

Shareholding Pattern

Insiders
0.57%
Institutions
104.07%
Public Float
104.67%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 15.01% 32.71M $90.29M
2 Kynam Capital Management, LP 9.96% 21.70M $59.90M
3 Blackrock Inc. 8.06% 17.56M $48.47M
4 Bank of America Corporation 6.92% 15.08M $41.63M
5 State Street Corporation 5.39% 11.75M $32.42M
6 Perceptive Advisors Llc 4.79% 10.44M $28.81M
7 Vanguard Capital Management LLC 3.91% 8.53M $23.53M
8 Point72 Asset Management, L.P. 3.58% 7.81M $21.56M
9 Wellington Management Group, LLP 2.37% 5.17M $14.27M
10 Venrock Adviser, LLC 2.29% 4.98M $13.75M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CTMX

Google News Fri, 19 Jun 2026

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNY2xVNDFoLTFKUHhRcUNqYTVWc0lPRU9HM1ZETzJ5eVRQamJYYlF6LTdrMThXcEIxUVZhS1BCYlVxWmtjcmF5b1VWdmtjR3J2MUF1TjZUenFRd0tUWE5qTXhnSU9VRld3eHNRdUZPd0dUMEM4UUJLY1QxY0RtZjlfcFJTZElTd0V4RHRtWm…

Google News ue, 01 Sep 2026

CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQXR6SWtuNkxLTzZ4bG5XTmF1TVJZOUw1LThadEoyQW40NUlJMzZqSXFkem1xVm8wMjhhOThNUHFVd1piRml4WVo1SkVxN2NLVXFka3J1SFlJanR6dFZWazFReGV4SmpyRDU4OWhIaDhMQTZLaGdaVVdDS21kbmdyZVNVTVd2bWR1QnhzN2…

Google News hu, 25 Jun 2026

CTMX Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5NOVZBOUlDWUp1VU9NblhwTjhPUWRGR0E0TGZfZk9xUkxmd1JHbTBJempocTg5RHU2NGh1ZTI0eFBLUmxWZ3dITXJzZDAyZ2c2X3QtSGJiUEtFSW5VWG9yYlpaTVZyQzl2eWFDU0hORHBDbUplR2FwcEFB?oc=5" target="_blank">CTM…

Google News Sat, 08 Aug 2026

CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNQ0lfdUo1YlZScEZBenB4OWc2LVZmNVZGYTU2clBhSDNTcTlzeGVRRkM2V2hOZDhIWHg4ZlRzZE5tSE4yREx2VEpZUlUtQmt1Z0JZSXByR3pqdnZLR1BoMXNPamlpZ2g4VXlJSkdtY2VzOTRuNW9feXh1bWktc0FRMEs4QWptR2VfRjU2bj…

Google News ue, 02 Dec 2025

$CTMX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQR3JpaTFWcEE0dTh4OHdmUFlFM09JaG1hMDFxT0p1Z1diNEtDME9rQzNrNEsxWFNTaHNTclZXVWRHRDBnLWUyY3EyQTRJZDJ5RE1jeDlqWE13UFlyU1Q3OG9sb1VNUnRpVVh3Q2I1aGp4b05wNnpsZ0RlYjR4MjhZOU90RkF1Vk0xRzJjTH…

Google News Wed, 08 Jul 2026

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOQnVqUUhuMndLVkFDaE9wemtpTGdleENrZ0E3TFRJZUNadEFCNC1PTk5Fc3lqV2ZxdUwwX2VEcmp4Y3ZxUm4ycDhsZHd1YmpMYmRxWnRHOTdFVHpabWZLcm5mWnJIc3dfM0pNdGxwckQ0UjhWZlRIalNiMl9wUS0tOElkQ0s2eTZ5enhGQX…

CTMX — Frequently Asked Questions

What is the current share price of CytomX Therapeutics, Inc. (CTMX)?

As of 2026-09-19 21:16 PDT, CytomX Therapeutics, Inc. (CTMX) trades at $3.65 on NasdaqGS. Its 52-week range is $1.76 to $6.75.

What is the market capitalisation of CTMX?

CytomX Therapeutics, Inc. (CTMX) has a market capitalisation of $795.33M on NasdaqGS.

What is the P/E ratio of CTMX?

CTMX trades at a trailing price-to-earnings (P/E) ratio of -6.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.55.

What is the return on equity (ROE) of CTMX?

CTMX has a return on equity (ROE) of -37.75%. Its return on capital employed (ROCE) is -21.31%.

Is CTMX a good stock to buy?

This page provides a data-driven analysis of CytomX Therapeutics, Inc. (CTMX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space